Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO LARIN FE vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) inhibits gonadotropin release, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial lining, reducing implantation likelihood.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
FDA: Prevention of pregnancy,Off-label: Treatment of dysmenorrhea, endometriosis, menstrual irregularities, acne vulgaris
Prevention of pregnancy
One tablet orally once daily for 28 consecutive days. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg. Active tablets (21 days) followed by ferrous fumarate 75 mg inert tablets (7 days).
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Ethinyl estradiol: ~13-17 hours; norethindrone: ~8-12 hours; steady-state achieved within 5-7 days; clinical significance: missed doses may require backup contraception.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol: primarily metabolized via CYP3A4; norethindrone: reduced to active metabolite (ethynylestradiol) and also metabolized via CYP3A4. Both undergo conjugation (glucuronidation and sulfation).
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: 30-50% as ethinyl estradiol metabolites and norethindrone metabolites; fecal: 30-50% primarily as norethindrone metabolites; biliary excretion contributes to enterohepatic circulation.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Ethinyl estradiol: ~97-98% bound to albumin and sex hormone-binding globulin (SHBG); norethindrone: ~90-95% bound to albumin and SHBG.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: ~3-4 L/kg; norethindrone: ~4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: ethinyl estradiol ~40-50% (first-pass metabolism); norethindrone ~60-70% (low first-pass effect).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in acute renal disease or renal impairment with decreased renal function due to potential fluid retention and hyperkalemia.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in acute hepatic disease, hepatic adenoma, or history of cholestatic jaundice. For mild Child-Pugh A: no data; use with caution. Moderate to severe (Child-Pugh B or C): contraindicated.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use before menarche. Post-menarche adolescents: same dosing as adults (one tablet daily) with monitoring for thromboembolic risk.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women. No specific geriatric dosing; avoid in women over 50 due to increased cardiovascular and thromboembolic risks.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thromboembolic disorders (VTE, stroke, MI) - increased risk especially in smokers >35,Carcinogenesis: possible increased risk of breast and cervical cancer,Hepatic effects: cholestatic jaundice, liver tumors,Gallbladder disease,Elevated blood pressure,COC use does not protect against HIV or other STDs,Ocular changes: retinal thrombosis, contact lens intolerance,Depression,Reduced efficacy with enzyme-inducing drugs
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Carcinoma of the endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes/day) and age >35
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but is generally not a concern. Iron absorption from the placebo pills is enhanced by taking with vitamin C (e.g., citrus fruits).
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Pregnancy category X. Contraindicated in pregnancy. First trimester: Risk of cardiovascular defects, oral clefts, neural tube defects. Second and third trimesters: Risk of feminization of male fetus, hepatic adenoma, and possible reduced birth weight.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Enters breast milk. M/P ratio unknown. May reduce milk production and affect infant hormone levels. Use caution; consider risks vs benefits.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Contraindicated in pregnancy; no dosing adjustments recommended. Alternative therapy should be used if pregnancy occurs.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
LO LARIN FE is a combination oral contraceptive containing norethindrone acetate and ethinyl estradiol with ferrous fumarate as a dietary supplement. Advise patients to take the active pills at the same time daily to maintain consistent hormone levels. The iron in the placebo pills is not sufficient for treating anemia but helps maintain iron stores. Instruct patients to start the first pack on the first day of menstrual bleeding. Missed doses increase the risk of breakthrough bleeding and contraceptive failure. Counsel that use of certain anticonvulsants, antibiotics, or St. John's wort can reduce efficacy.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one tablet daily at the same time each day. Do not skip doses.,The 24th to 28th pills are placebo and contain iron; they are not for contraception.,If you miss a dose, refer to the package insert instructions. Two missed pills may require backup contraception.,Smoking increases the risk of serious cardiovascular side effects, especially if you are over 35.,Report symptoms of blood clots, such as leg pain, chest pain, or sudden shortness of breath immediately.,This medication does not protect against sexually transmitted infections.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO LARIN FE vs ALYACEN 7/7/7, answered by our medical review team.
LO LARIN FE is a Oral Contraceptive that works by Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) inhibits gonadotropin release, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial lining, reducing implantation likelihood.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO LARIN FE and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO LARIN FE is: One tablet orally once daily for 28 consecutive days. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg. Active tablets (21 days) followed by ferrous fumarate 75 mg inert tablets (7 days).. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO LARIN FE and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO LARIN FE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. First trimester: Risk of cardiovascular defects, oral clefts, neural tube defects. Second and third trimesters: Risk of feminiza. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.